论文部分内容阅读
初步临床试验表明,benazepril是新的具有口服活性的有效的ACE抑制剂,且耐受性良好。30例轻度至中度特发性高血压(WHO1或2级)门诊患者(平均年龄51岁),先服2周安慰剂,仰卧位舒张血压≥95mmHg,接着服用本品20mg每日1次,连续2周,如果舒张压<95mmHg(标准),继续用原剂量治疗4周;如治疗2周后,舒张压仍≥95mmHg,则20mg每日2次,继续治疗4周。服用本品2周后,平均仰卧位和静息时血压显著降低(与治疗前对照),分别为148.3/87.5与163.9/100.7mmHg和148.9/
Preliminary clinical trials have shown that benazepril is a potent ACE inhibitor that is orally active and well tolerated. Thirty patients (mean age 51 years) from outpatients with mild to moderate essential hypertension (WHO1 or 2) received placebo for 2 weeks, diastolic blood pressure ≥ 95 mmHg in supine position, and 20 mg once daily , Continuous 2 weeks, if the diastolic blood pressure <95mmHg (standard), continue to use the original dose for 4 weeks; such as 2 weeks after treatment, the diastolic blood pressure is still ≥ 95mmHg, then 20mg twice daily for 4 weeks. After taking this product for 2 weeks, the average supine position and resting blood pressure decreased significantly (compared with pre-treatment control), which were 148.3 / 87.5 and 163.9 / 100.7mmHg and 148.9 /